|
業務類別
|
-- |
|
業務概覽
|
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers. |
| 公司地址
| No. 699 Zhong Ke Road, 5th Floor, Building B, Pudong New District, Shanghai, CHN |
| 電話號碼
| +86 2150464201 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.jwtherapeutics.com |
| 員工數量
| 281 |
| Mr. Yiping James Li |
Chairman of the Board and Chief Executive Officer |
-- |
26/04/2023 |
|
|
| Mr. Yiping James Li |
Chairman of the Board and Chief Executive Officer |
26/04/2023 |
| Dr. Debra Yu, M.D. |
Independent Director |
26/04/2023 |
| Mr. Kin Cheong Kelvin Ho |
Independent Director |
26/04/2023 |
| Dr. Krishnan Viswanadhan |
Director |
26/04/2023 |
| Ms. Xing Gao |
Director |
26/04/2023 |
| Dr. Ann Li Lee, PhD |
Director |
26/04/2023 |
| Mr. Jinyin Wang |
Director |
26/04/2023 |
| Dr. Cheng Liu, PhD |
Director |
26/04/2023 |
| Mr. Yiu Leung Cheung |
Independent Director |
26/04/2023 |
|
|
|
|
